Plus Therapeutics (NASDAQ:CNSY) Posts Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:CNSY) issued its earnings results on Friday. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.16), FiscalAI reports. The business had revenue of $0.72 million for the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%.

Plus Therapeutics Price Performance

Shares of Plus Therapeutics stock traded up $0.18 during trading on Friday, reaching $0.95. The company’s stock had a trading volume of 8,046,110 shares, compared to its average volume of 443,996. The stock has a 50-day moving average of $1.74. Plus Therapeutics has a one year low of $0.43 and a one year high of $18.89. The firm has a market capitalization of $7.21 million, a PE ratio of -0.28 and a beta of 1.49.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CNSY shares. Zacks Research cut Plus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Monday, November 2nd. Two research analysts have rated the stock with a Sell rating. Based on data from MarketBeat.com, Plus Therapeutics has an average rating of “Sell”.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. Its lead investigational product is Rhenium-186 NanoLiposome (RNL), a proprietary formulation designed to deliver the radioactive isotope rhenium-186 directly to tumors while limiting exposure to surrounding healthy tissue. The company has focused its development programs primarily on central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases.